{"title":"Actelion获得Auxilium的Xiaflex®在加拿大、澳大利亚、巴西和墨西哥的权利","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I3.1692","DOIUrl":null,"url":null,"abstract":"Actelion Pharmaceuticals has gained the rights to develop and commercialise Auxilium Pharmaceuticals’ Xiaflex® (collagenase clostridium histolyticum), a first-in-class biologic for Dupuytren’s contracture (DC) and Peyronie’s disease (PD), in Canada, Australia, Brazil and Mexico in a deal worth up to US$68.5 M. The drug has already received regulatory approval in the US and Europe for DC and has been accepted for review for this indication in Canada. Auxilium will continue to assume primary responsibility for the drug’s ongoing Phase III development programme for PD, data from which are expected late in the second half of 2012.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"40 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I3.1692\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Actelion Pharmaceuticals has gained the rights to develop and commercialise Auxilium Pharmaceuticals’ Xiaflex® (collagenase clostridium histolyticum), a first-in-class biologic for Dupuytren’s contracture (DC) and Peyronie’s disease (PD), in Canada, Australia, Brazil and Mexico in a deal worth up to US$68.5 M. The drug has already received regulatory approval in the US and Europe for DC and has been accepted for review for this indication in Canada. Auxilium will continue to assume primary responsibility for the drug’s ongoing Phase III development programme for PD, data from which are expected late in the second half of 2012.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"40 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I3.1692\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I3.1692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Actelion Pharmaceuticals已获得Auxilium Pharmaceuticals的Xiaflex®(胶原酶溶组织梭菌)在加拿大、澳大利亚、巴西和墨西哥的开发和商业化权利，该药物是治疗Dupuytren ' s挛缩(DC)和Peyronie ' s disease (PD)的一流生物制剂，价值高达6850万美元。该药物已在美国和欧洲获得DC的监管批准，并已在加拿大接受该适应症的审查。Auxilium将继续承担该药正在进行的PD III期开发项目的主要责任，该项目的数据预计将于2012年下半年公布。
Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico
Actelion Pharmaceuticals has gained the rights to develop and commercialise Auxilium Pharmaceuticals’ Xiaflex® (collagenase clostridium histolyticum), a first-in-class biologic for Dupuytren’s contracture (DC) and Peyronie’s disease (PD), in Canada, Australia, Brazil and Mexico in a deal worth up to US$68.5 M. The drug has already received regulatory approval in the US and Europe for DC and has been accepted for review for this indication in Canada. Auxilium will continue to assume primary responsibility for the drug’s ongoing Phase III development programme for PD, data from which are expected late in the second half of 2012.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
